“Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s607. https://doi.org/10.25251/qx64pd52.